Endpoints News
Lonza looks to ride ADC wave with upcoming factory Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
6 May, 2026
DIA 2026 - GLOBAL ANNUAL MEETING
Where regulators and industry align on what's next.
sponsored by DIA
presented by Premier, Inc.
Ex­ec­u­tive Brief: How to Fu­ture-Proof and Dif­fer­en­ti­ate Your Busi­ness with RWD/RWE
top stories
1. Amgen, AbbVie say IRA negotiations impacted Q1 sales
2. Lonza looks to ride ADC wave with upcoming factory, workforce expansion
3. Lilly allots $4.5B for new manufacturing projects across Indiana
4. BeOne culls five cancer programs and an autoimmune Phase 2
5. Novo Nordisk's first quarter in four words: Pills, pricing, payments and pressure
6. GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane
7. Bayer dips toes back into pharma M&A to buy Perfuse Therapeutics
more stories
 
Lydia Ramsey Pflanzer
.

Nicole DeFeudis has been keeping tabs on how the first round of IRA prices has impacted sales since they went into effect at the start of the year. So far, AbbVie and Amgen have mentioned the hit to sales of drugs like Imbruvica and Enbrel.

.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
1
by Nicole DeFeudis

At least two drug­mak­ers say they’re feel­ing the im­pact of the In­fla­tion Re­duc­tion Act, af­ter the first drug prices ne­go­ti­at­ed un­der the law took ef­fect in Jan­u­ary...

Read full story
A worker operates an automatic filling machine at Lonza's facility in Stein, Switzerland (Credit: Lonza)
2
by Anna Brown

BASEL, Switzer­land— Lon­za said it wants to own the com­mer­cial mar­ket for an­ti­body-drug con­ju­gates, with a new man­u­fac­tur­ing site set to come on­line next...

Read full story
3
by Max Bayer

Eli Lil­ly is com­mit­ting to its roots, al­lo­cat­ing $4.5 bil­lion for new man­u­fac­tur­ing in­vest­ments across In­di­ana as drug­mak­ers pledge more US projects.

The world’s largest...

Read full story
4
by Kyle LaHucik

BeOne Med­i­cines has great­ly ex­pand­ed its pipeline over the years, bring­ing 18 new mol­e­c­u­lar en­ti­ties to the fore across 2024 and 2025. But that al­so...

Read full story
Mike Doustdar, Novo Nordisk CEO (Nichlas Pollier/Bloomberg via Getty Images)
5
by Elizabeth Cairns

A mil­lion pa­tients with obe­si­ty are al­ready tak­ing No­vo Nordisk’s We­govy pill, CEO Mike Doust­dar said Wednes­day, de­spite the mar­ket en­try of Lil­ly’s Foun­dayo.

Novo's...

Read full story
6
by Kyle LaHucik

GSK is fur­ther delv­ing in­to the car­diometa­bol­ic space — and deep­en­ing its re­la­tion­ship with Chi­na biotechs — in a $1 bil­lion biobucks deal with an...

Read full story